The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)
Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the effect of erdosteine, compared to placebo, on
exacerbation rate over a 12-month treatment period in patients with moderate-to-severe COPD.
Moreover, the effects of erdosteine on pulmonary function parameters, clinical symptoms and
quality of life, and the long-term safety of the drug will be assessed.